再鼎醫藥(09688.HK)完成美國包銷發售ADR 每股150美元
再鼎醫藥(09688.HK)公布,已向美國證交會提交8-K表格,完成於美國包銷發售477.6萬股美國預託股份(ADR),每股ADR代表1股普通股,價格為每股ADR 150美元。公司已授予ADR發售包銷商30日選擇權,以按發售價額外購買最多71.64萬股ADR。包銷商已悉數行使彼等之選擇權以購買該等額外ADR。相關ADR發售已於上周五(23日)完成。
公司預期全球發售所得款項總額合共約為8.58億美元,公司來自ADR發售之所得款項總額約8.24億美元。普通股發售預期將於周三(28日)或前後完成,將以港元結算,價格為每股普通股1,164.2元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.